Cargando…

Rational design of a multi-valent human papillomavirus vaccine by capsomere-hybrid co-assembly of virus-like particles

The capsid of human papillomavirus (HPV) spontaneously arranges into a T = 7 icosahedral particle with 72 L1 pentameric capsomeres associating via disulfide bonds between Cys175 and Cys428. Here, we design a capsomere-hybrid virus-like particle (chVLP) to accommodate multiple types of L1 pentamers b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Daning, Liu, Xinlin, Wei, Minxi, Qian, Ciying, Song, Shuo, Chen, Jie, Wang, Zhiping, Xu, Qin, Yang, Yurou, He, Maozhou, Chi, Xin, Huang, Shiwen, Li, Tingting, Kong, Zhibo, Zheng, Qingbing, Yu, Hai, Wang, Yingbin, Zhao, Qinjian, Zhang, Jun, Xia, Ningshao, Gu, Ying, Li, Shaowei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275066/ https://www.ncbi.nlm.nih.gov/pubmed/32503989 http://dx.doi.org/10.1038/s41467-020-16639-1

Ejemplares similares

Neutralization sites of human papillomavirus-6 relate to virus attachment and entry phase in viral infection
por: Liu, Xinlin, et al.
Publicado: (2019)

Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificity
por: Li, Zhihai, et al.
Publicado: (2018)

N-terminal truncations on L1 proteins of human papillomaviruses promote their soluble expression in Escherichia coli and self-assembly in vitro
por: Wei, Minxi, et al.
Publicado: (2018)

Structural Basis for the Shared Neutralization Mechanism of Three Classes of Human Papillomavirus Type 58 Antibodies with Disparate Modes of Binding
por: He, Maozhou, et al.
Publicado: (2021)

Characterization of an Escherichia coli-derived triple-type chimeric vaccine against human papillomavirus types 39, 68 and 70
por: Qian, Ciying, et al.
Publicado: (2022)

Recent Progress on the Versatility of Virus-Like Particles
por: Qian, Ciying, et al.
Publicado: (2020)

Crystal Structures of Two Immune Complexes Identify Determinants for Viral Infectivity and Type-Specific Neutralization of Human Papillomavirus
por: Li, Zhihai, et al.
Publicado: (2017)

Viral neutralization by antibody-imposed physical disruption
por: Zheng, Qingbing, et al.
Publicado: (2019)

Engineering for an HPV 9-valent vaccine candidate using genomic constitutive over-expression and low lipopolysaccharide levels in Escherichia coli cells
por: Wang, Kaihang, et al.
Publicado: (2021)

Omics-guided bacterial engineering of Escherichia coli ER2566 for recombinant protein expression
por: Zhou, Lizhi, et al.
Publicado: (2022)

Antigenic presentation of heterologous epitopes engineered into the outer surface-exposed helix 4 loop region of human papillomavirus L1 capsomeres
por: Murata, Yoshihiko, et al.
Publicado: (2009)

Current progress in the development of prophylactic and therapeutic vaccines
por: Li, Tingting, et al.
Publicado: (2022)

A stepwise docking molecular dynamics approach for simulating antibody recognition with substantial conformational changes
por: Huang, Yang, et al.
Publicado: (2022)

A human monoclonal antibody against HPV16 recognizes an immunodominant and neutralizing epitope partially overlapping with that of H16.V5
por: Xia, Lin, et al.
Publicado: (2016)

Identification of Broad-Genotype HPV L2 Neutralization Site for Pan-HPV Vaccine Development by a Cross-Neutralizing Antibody
por: Wang, Daning, et al.
Publicado: (2015)

Genome re-sequencing and reannotation of the Escherichia coli ER2566 strain and transcriptome sequencing under overexpression conditions
por: Zhou, Lizhi, et al.
Publicado: (2020)

T = 4 Icosahedral HIV-1 Capsid As an Immunogenic Vector for HIV-1 V3 Loop Epitope Display
por: Zhang, Zhiqing, et al.
Publicado: (2018)

Structures of pseudorabies virus capsids
por: Wang, Guosong, et al.
Publicado: (2022)

Construction of a bacterial surface display system based on outer membrane protein F
por: Chen, Tingting, et al.
Publicado: (2019)

Capsid destabilization and epitope alterations of human papillomavirus 18 in the presence of thimerosal
por: Huang, Xiaofen, et al.
Publicado: (2021)

A Bacterially Expressed SARS-CoV-2 Receptor Binding Domain Fused With Cross-Reacting Material 197 A-Domain Elicits High Level of Neutralizing Antibodies in Mice
por: Liu, Liqin, et al.
Publicado: (2022)

Structural characterization of a neutralizing mAb H16.001, a potent candidate for a common potency assay for various HPV16 VLPs
por: Huang, Weijin, et al.
Publicado: (2020)

HER3-targeted protein chimera forms endosomolytic capsomeres and self-assembles into stealth nucleocapsids for systemic tumor homing of RNA interference in vivo
por: Alonso-Valenteen, Felix, et al.
Publicado: (2019)

Characterization and immunogenicity of SARS-CoV-2 spike proteins with varied glycosylation
por: Deng, Tingting, et al.
Publicado: (2022)

SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates
por: Li, Tingting, et al.
Publicado: (2020)

Neutralizing antibodies against SARS-CoV-2: current understanding, challenge and perspective
por: Huang, Yang, et al.
Publicado: (2020)

Baculovirus Display of Varicella–Zoster Virus Glycoprotein E Induces Robust Humoral and Cellular Immune Responses in Mice
por: Xue, Wenhui, et al.
Publicado: (2022)

Chimeric Virus-Like Particles and Capsomeres Induce Similar CD8(+) T Cell Responses but Differ in Capacity to Induce CD4(+) T Cell Responses and Antibody Responses
por: Pattinson, David J., et al.
Publicado: (2020)

Identification of a cross-neutralizing antibody that targets the receptor binding site of H1N1 and H5N1 influenza viruses
por: Li, Tingting, et al.
Publicado: (2022)

Discovery and structural characterization of a therapeutic antibody against coxsackievirus A10
por: Zhu, Rui, et al.
Publicado: (2018)

A Broad Safety Assessment of the 9-Valent Human Papillomavirus Vaccine
por: Yih, W Katherine, et al.
Publicado: (2021)

Systemic lupus erythematosus following human papillomavirus 9-valent vaccination
por: Wan, Yuehua, et al.
Publicado: (2022)

Extended surveillance to assess safety of 9-valent human papillomavirus vaccine
por: Sundaram, Maria E., et al.
Publicado: (2022)

Prophylactic Hepatitis E Vaccines: Antigenic Analysis and Serological Evaluation
por: Li, Yike, et al.
Publicado: (2020)

Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants
por: Li, Tingting, et al.
Publicado: (2021)

Myasthenia gravis after the third dose of human papillomavirus 9-valent vaccine: A case report
por: Ding, Yuan, et al.
Publicado: (2023)

Molecular and functional analysis of monoclonal antibodies in support of biologics development
por: Wang, Xin, et al.
Publicado: (2017)

Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease
por: Serrano, Beatriz, et al.
Publicado: (2012)

Safety of Human Papillomavirus 9-Valent Vaccine: A Meta-Analysis of Randomized Trials
por: Costa, Ana Paula Ferreira, et al.
Publicado: (2017)

Immune escape by SARS-CoV-2 Omicron variant and structural basis of its effective neutralization by a broad neutralizing human antibody VacW-209
por: Ju, Bin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_92ngfdp9562hhdhr68ug7bgt04